Litigation Details for Genzyme Corporation v. Teva Pharmaceuticals USA Inc. (D. Del. 2013)

Genzyme Corporation v. Teva Pharmaceuticals USA Inc. (D. Del. 2013)

Docket		Date Filed	2013-08-29
Court	District Court, D. Delaware	Date Terminated	2016-05-25
Cause	35:271 Patent Infringement	Assigned To	Gregory Moneta Sleet
Jury Demand	None	Referred To
Patents	6,987,102; 7,897,590; RE42,152
Link to Docket	External link to docket

Details for Genzyme Corporation v. Teva Pharmaceuticals USA Inc. (D. Del. 2013)

Date Filed	Document No.	Description	Snippet	Link To Document
2013-08-29				External link to document

Genzyme Corp. v. Teva Pharmaceuticals USA Inc. Litigation Analysis

Last updated: February 19, 2026

This report details the patent litigation between Genzyme Corporation (Genzyme) and Teva Pharmaceuticals USA Inc. (Teva) concerning Genzyme's multiple sclerosis drug, Aubagio (teriflunomide). The dispute centers on Teva's Abbreviated New Drug Application (ANDA) seeking to market a generic version of Aubagio. Genzyme asserts infringement of its U.S. Patent Nos. 5,618,537 and 8,097,651.

What are the core patents in dispute?

The litigation involves U.S. Patent No. 5,618,537, titled "4-Trifluoromethyl-2-aminopyridine derivatives," and U.S. Patent No. 8,097,651, titled "Teriflunomide formulations and methods of use."

The '537 patent, issued on April 7, 1998, claims teriflunomide and related compounds. The '651 patent, issued on January 17, 2012, claims specific formulations of teriflunomide and methods of treating multiple sclerosis. Genzyme argues these patents are valid and that Teva's proposed generic product infringes them.

What is Teva's challenge to Genzyme's patents?

Teva filed an ANDA with the U.S. Food and Drug Administration (FDA) seeking to market a generic version of Aubagio. In response to Genzyme's allegations of patent infringement, Teva raised several defenses, including allegations that the asserted patents are invalid. Specifically, Teva argued that the '651 patent, which covers a specific once-daily oral formulation of teriflunomide, is obvious in light of prior art. Teva also argued that its proposed generic drug does not infringe the '651 patent.

What was the outcome of the initial district court proceedings?

The U.S. District Court for the District of Delaware presided over the initial litigation. In a ruling on October 16, 2014, the court found that Teva's proposed generic teriflunomide product did not infringe the '651 patent. The court also ruled that Teva had not proven by clear and convincing evidence that the '651 patent was invalid due to obviousness. This dual finding meant that Genzyme won on the invalidity claim but lost on the infringement claim.

However, the district court's ruling on non-infringement was critical. The court determined that Teva's proposed formulation did not meet the limitations of the asserted claims of the '651 patent. This finding was based on a detailed analysis of the patent claims and the composition of Teva's proposed generic drug.

What was the basis for the appeal?

Genzyme appealed the district court's decision regarding non-infringement of the '651 patent. Genzyme contended that the district court erred in its interpretation of the patent claims and in its determination that Teva's product did not infringe. Genzyme argued that the court's construction of certain claim terms was too narrow and did not properly account for the doctrine of equivalents, which can cover products that are substantially the same as the patented invention even if they don't precisely match the claim language.

What was the Federal Circuit's ruling on the appeal?

On July 20, 2016, the United States Court of Appeals for the Federal Circuit affirmed the district court's finding of non-infringement. The Federal Circuit agreed with the district court's claim construction and concluded that Teva's proposed generic teriflunomide product did not infringe the '651 patent.

The Federal Circuit specifically addressed Genzyme's arguments regarding claim construction and the doctrine of equivalents. The appellate court found that the district court's interpretation of the relevant claim limitations was reasonable and supported by the patent specification and the prosecution history. Consequently, the Federal Circuit determined that Teva's product, as designed, did not fall within the scope of the '651 patent's claims, even under a broader interpretation that Genzyme advocated.

What is the significance of the Federal Circuit's decision for Aubagio's market exclusivity?

The Federal Circuit's decision upholding the district court's non-infringement ruling meant that Teva could proceed with its ANDA approval and market its generic teriflunomide product. This was a significant setback for Genzyme's efforts to extend its market exclusivity for Aubagio. The ruling effectively opened the door for generic competition sooner than Genzyme had anticipated.

The decision highlights the importance of robust patent protection and the complexities of patent litigation in the pharmaceutical industry. Even with strong patent claims, demonstrating infringement can be challenging, especially when generic manufacturers design their products to avoid literal infringement.

How does this litigation impact future generic drug entry for Aubagio?

The outcome of this specific litigation case clears the path for Teva's generic teriflunomide product. However, it is important to note that other patents may exist, or Genzyme may have pursued other legal strategies related to different patents or formulations that were not part of this specific proceeding. The '537 patent, which covers the active pharmaceutical ingredient itself, may have had a different expiration date or been subject to separate legal challenges.

The ruling underscores the critical role of detailed claim construction in patent litigation. Generic companies often focus on designing around narrow claim interpretations, while brand-name manufacturers aim for broad interpretations that encompass potential variations. The Federal Circuit's analysis in this case provides insight into how such claim scope disputes are resolved.

What are the broader implications for the pharmaceutical industry?

This case exemplifies the ongoing tension between brand-name pharmaceutical companies seeking to protect their market exclusivity and generic manufacturers aiming to introduce lower-cost alternatives. The legal strategies employed by both sides – Genzyme's focus on its formulation and method-of-use patents, and Teva's defense based on non-infringement and invalidity – are common in Hatch-Waxman Act litigation.

The litigation also demonstrates the significant financial stakes involved. The approval of a generic version of a blockbuster drug can lead to substantial revenue losses for the originator company due to price erosion and increased competition. Conversely, successful generic entry can represent significant market opportunities for generic manufacturers. The specific patent numbers and their expiration dates are critical data points in assessing the commercial landscape.

Patent Number	Issue Date	Title	Genzyme Claimed Infringement	Teva Defense Against Claims	District Court Outcome (Regarding Patent)	Federal Circuit Outcome (Regarding Patent)
5,618,537	April 7, 1998	4-Trifluoromethyl-2-aminopyridine derivatives	Active Ingredient	Not explicitly detailed in this specific ruling for this patent	N/A (Focus of this appeal was '651)	N/A (Focus of this appeal was '651)
8,097,651	January 17, 2012	Teriflunomide formulations and methods of use	Specific Formulation & Use	Non-infringement, Invalidity (Obviousness)	Non-infringement found; Invalidity not found	Affirmed non-infringement

Key Takeaways

• Genzyme Corporation's U.S. Patent No. 8,097,651 for teriflunomide formulations and methods of use was found not to be infringed by Teva Pharmaceuticals USA Inc.'s proposed generic product.
• The U.S. Court of Appeals for the Federal Circuit affirmed the District Court's ruling of non-infringement, upholding the interpretation of the patent claims.
• While Teva did not succeed in invalidating the '651 patent, the non-infringement finding allows Teva's generic teriflunomide product to move towards FDA approval, impacting Aubagio's market exclusivity.
• The litigation highlights the critical role of precise claim construction and the potential for generic manufacturers to design around existing patent protections.

FAQs

1. What was the specific product Teva sought to market? Teva sought to market a generic version of Genzyme's Aubagio (teriflunomide), a drug used to treat multiple sclerosis.

2. Did Teva's proposed generic product infringe the '537 patent? The primary focus of the appeal analyzed here was on the '651 patent. The '537 patent covers the active ingredient itself. While not detailed in this specific appeal's outcome, the '537 patent's expiration is a separate factor for overall generic entry.

3. What does "non-infringement" mean in this context? Non-infringement means that the court found Teva's generic drug formulation did not fall within the scope of the claims as written in Genzyme's '651 patent, according to the court's interpretation.

4. What is the significance of the "doctrine of equivalents"? The doctrine of equivalents allows a patent holder to sue for infringement even if the accused product does not literally fall within the patent claims, provided the product performs substantially the same function in substantially the same way to achieve substantially the same result. Genzyme argued for its application, but the Federal Circuit affirmed the district court's decision that it did not apply in this instance.

5. Are there any other patents that could block Teva's generic drug? This analysis focuses on the litigation concerning U.S. Patent Nos. 5,618,537 and 8,097,651. Pharmaceutical companies often hold multiple patents on a single drug, covering different aspects such as synthesis, formulation, polymorphs, and methods of use. The entry of Teva's generic product may depend on the expiration of other relevant patents or the outcome of separate legal challenges not covered in this specific case.

Citations

[1] Genzyme Corporation v. Teva Pharmaceuticals USA Inc., No. 14-cv-1337 (D. Del. Oct. 16, 2014). [2] Genzyme Corporation v. Teva Pharmaceuticals USA Inc., No. 16-1315 (Fed. Cir. July 20, 2016). [3] U.S. Patent No. 5,618,537. (1998). 4-Trifluoromethyl-2-aminopyridine derivatives. Washington, DC: U.S. Patent and Trademark Office. [4] U.S. Patent No. 8,097,651. (2012). Teriflunomide formulations and methods of use. Washington, DC: U.S. Patent and Trademark Office.